[Lu-177]-PNT2002
- Generic Name
- [Lu-177]-PNT2002
Expanded Access Treatment with [Lu-177]-PNT2002 for Adult Patients with Prostate-Specific Membrane Antigen (PSMA)-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Conditions
- Castration-Resistant Prostatic Cancer
- First Posted Date
- 2023-09-13
- Last Posted Date
- 2025-01-13
- Lead Sponsor
- Lantheus Medical Imaging
- Registration Number
- NCT06033001
- Locations
- 🇺🇸
Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States
🇺🇸Hartford HealthCare Cancer Institute at Hartford Hospital, Hartford, Connecticut, United States
🇺🇸Florida Theranostics Cancer Center, Jupiter, Florida, United States
Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment
Phase 3
Active, not recruiting
- Conditions
- Metastatic Castration-Resistant Prostate Cancer
- Interventions
- First Posted Date
- 2020-12-01
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company
- Target Recruit Count
- 415
- Registration Number
- NCT04647526
- Locations
- 🇺🇸
VA Greater Los Angeles Healthcare System, Los Angeles, California, United States
🇺🇸Greater Dayton Cancer Center, Kettering, Ohio, United States
🇺🇸Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath